Related Experiment Video

Updated: May 28, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors

S Walsh1, L Flanagan, C Quinn

  • 1UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland.

Breast (Edinburgh, Scotland)
|October 4, 2011
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies. This study found increased nuclear p-mTOR in TNBC, suggesting mTOR as a potential new therapeutic target for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies due to the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 overexpression.
  • The mTOR pathway regulates cancer cell growth, survival, and invasion, presenting a potential therapeutic target in TNBC.

Purpose of the Study:

  • To investigate the role of mTOR signaling in TNBC progression.
  • To determine if mTOR or its phosphorylated form (p-mTOR) are differentially expressed in TNBC compared to non-TNBC.

Main Methods:

  • Immunohistochemistry was used to measure mTOR and p-mTOR expression.
  • Samples included 89 TNBCs and 99 non-TNBCs.

Main Results:

  • mTOR expression was primarily cytoplasmic in tumor cells.
  • p-mTOR staining was observed in the nucleus, perinuclear area, and cytoplasm.
  • Nuclear p-mTOR was significantly more frequent in TNBC than in non-TNBC (p < 0.001).

Conclusions:

  • The findings suggest a more significant role for mTOR in the progression of TNBC compared to other breast cancer subtypes.
  • mTOR signaling, particularly nuclear p-mTOR, may represent a novel therapeutic target for triple-negative breast cancer.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...